



P.O. Box 8738, Dayton, OH 45401-8738 | CareSource.com

Re: Summary of PDL Changes Effective October 1, 2022

Dear CareSource Member:

Your health care is our priority. That is why we are writing to tell you that on October 1, 2022, CareSource will change its Preferred Drug List (PDL). A PDL is a list of preferred drugs.

THE FOLLOWING MEDICINES WILL BE PREFERRED ON THE PDL EFFECTIVE OCTOBER 1, 2022.

Brand Name	Generic Name	Dose(s)	Notes – If Applicable
Insulin Lispro Pen, Vial	Insulin Lispro	100 unit/mL	
Insulin Lispro Jr. Pen	Insulin Lispro	100 unit/mL	

THE FOLLOWING MEDICINES WILL BE NON-PREFERRED ON THE PDL EFFECTIVE OCTOBER 1, 2022.

Brand Name	Generic Name	Dose(s)	Notes – If Applicable
Admelog Solostar, Vial	Insulin Lispro	100 unit/mL	Preferred product: Insulin Lispro 100 unit/mL Pen, Vial, or Jr.

THE FOLLOWING MEDICINES HAVE A CHANGE IN STATUS EFFECTIVE OCTOBER 1, 2022.

Brand Name	Generic Name	Dose(s)	Notes – If Applicable
Belsomra Tablet	Suvorexant	5 mg, 10 mg, 15 mg, 20 mg	Will now require prior authorization for members <18 years old
Qelbree Capsule	Viloxazine	100 mg, 150 mg, 200 mg	Will no longer require prior authorization for members ≥18 years old

What should you do?

First, talk to your prescriber. There may be other medicines on the CareSource PDL that you can take instead. There are a few ways you and your prescriber can find medicines:

- You can look on our website at **CareSource.com**. On the Members page, go to Tools & Resources and click on “Find My Prescriptions.”
- Or, call our Member Services Department at **1-844-607-2829** (TTY: **1-800-743-3333** or **711**).

We are here to help you. The CareSource Member Services Department is open Monday through Friday, 8 a.m. to 8 p.m.

Sincerely,

CareSource RX Innovations

CareSource complies with applicable state and federal civil rights laws and does not discriminate on the basis of age, gender, gender identity, color, race, disability, national origin, marital status, sexual preference, religious affiliation, health status, or public assistance status.

IN-MMED-1895b-V.24; First Use: 3/7/2019

OMPP Approved: 3/7/2019